Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03109925|
Recruitment Status : Not yet recruiting
First Posted : April 12, 2017
Last Update Posted : April 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Benign Prostatic Hyperplasia||Device: DC Lumi Bead, BTG||Phase 2|
This is a study protocol for the use of a novel radiopaque embolic agent in the treatment of lower urinary tract Symptoms (LUTS) with prostatic artery embolisation (PAE). This study will allow us to evaluate the safety and efficacy of this embolic in PAE along with giving us a better understanding of embolic distribution. It would also give us answers to:
- How does embolic efficacy compare to current available embolic agents?
- Does enhancement on rotational CT correlate with embolic distribution?
- How does embolic distribution compare with tissue infarction?
- Does the density of embolic packing correlate with degree of infarction and volume loss?
- How predictable is superselective target embolisation?
- Does embolic distribution vary with anatomy and gland size?
- Does embolic distribution tally with glandular enhancement/ transitional zone vascularity?
- If visible, what is the effect and significance of non target embolisation? This is a cohort study aiming to recruit 22 patients to power a non-inferiority assessment comparing the novel embolic agent against current available embolics.
Data will be added to our on going local registry of patients who have undergone this procedure . This will provide information about how safe and effective it is for patients and how it compares to the other established embolic agents such as polyvinyl alcohol (PVA) and other spherical agents such as Embospheres and Embozenes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Single group of patients undergoing prostate artery embolization with a new embolic which is radio-opaque and can give a better idea of embolization distribution (DC Lumi Beads by BTG)|
|Masking:||None (Open Label)|
|Masking Description:||No masking|
|Official Title:||Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement|
|Estimated Study Start Date :||May 2017|
|Estimated Primary Completion Date :||May 2018|
|Estimated Study Completion Date :||May 2018|
Experimental: Radio-opaque embolic arm
Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic "Lumi-Bead" developed by BTG plc.
Device: DC Lumi Bead, BTG
Embolic agent which is radio-opaque
- Adverse event rate [ Time Frame: 12 months ]Rate of adverse events compared with currently available other embolic agents
- Scale of symptomatic improvement [ Time Frame: 12 months ]symptomatic improvement will be gauged used the internationally recognised IPSS questionnaire. Decrease in IPSS score in study participants will be compared against other embolic agents in the literature
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03109925
|Contact: Drew Macleanemail@example.com|
|Principal Investigator:||Timothy Bryant||University of Hospital Southampton|